Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Source: Nasdaq GlobeNewswire / 11 Jan 2024 08:00:00   America/New_York